Survival Analysis for Patients with ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.

MLA

Iwama, Eiji, et al. “Survival Analysis for Patients with ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.” Oncologist, vol. 25, no. 4, Apr. 2020, p. 306. EBSCOhost, https://doi.org/10.1634/theoncologist.2019-0728.

APA

Iwama, E., Goto, Y., Murakami, H., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., Bessho, A., Ono, M., Nishitsuji, M., Akamatsu, H., Morinaga, R., Akagi, T., Shimose, T., Tokunaga, S., Yamamoto, N., Nakanishi, Y., & Sugio, K. (2020). Survival Analysis for Patients with ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. Oncologist, 25(4), 306. https://doi.org/10.1634/theoncologist.2019-0728

Chicago

Iwama, Eiji, Yasushi Goto, Haruyasu Murakami, Shinsuke Tsumura, Hiroyuki Sakashita, Yoshiaki Mori, Noriaki Nakagaki, et al. 2020. “Survival Analysis for Patients with ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.” Oncologist 25 (4): 306. doi:10.1634/theoncologist.2019-0728.